Cytovance Biologics
Oklahoma City, OK
Compare Biologics CDMOs in USA
Compare Recombinant Proteins CDMOs in USA
Compare Plasmid DNA CDMOs in USA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
78.6
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (1)
Quick Facts: Cytovance Biologics
- Signal Score
- 78.6/100 (as of 2026-10-29)
- Quality Compliance
- 98.2/100
- Headquarters
- Oklahoma City, OK
- Founded
- 2006
- Max Bioreactor Scale
- 2,000L
- Website
- https://cytovance.com/
- Modalities
- Microbial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
98.2
FDA Inspections1 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2026-06-17)
Most Recent HC OutcomeCompliant · 2019-05-01
HC Attribution1 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMicrobial Fermentation, Biologics, Recombinant Proteins, Mammalian Cell Culture, Plasmid DNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
63.0
Broad modality coverage (5 modalities)
Sites: Oklahoma City, OK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
Broad modality coverage (5 modalities)
Sites: Oklahoma City, OK
Press Signals8 articles (not scored)
Broad modality coverage (5 modalities)
Cytovance Biologics FDA Inspection History
2026-06
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-06-17 |
Cytovance Biologics Inc.
Oklahoma City, Oklahoma
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
biologics · 1 site
- Oklahoma City, United States · Cytovance Biologics, Inc. — biologics · valid to Jul 8, 2030
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 8 articles
Company announcements, not verified evidence. They do not change any score.
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing BioSpace
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Sahm
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing - irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 with Selection of Cytovance Biologics for cGMP Manufacturing irw-press.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing StreetInsider
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Yahoo Finance Singapore
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer - geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine to Phase 2 Trials with Cytovance Biologics as cGMP Manufacturer geneonline.com
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing PR Newswire
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing - Morningstar
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing Morningstar
Frequently Asked Questions About Cytovance Biologics
How many FDA inspections does Cytovance Biologics have on record?
CDMO Signal tracks 1 FDA inspection for Cytovance Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has Cytovance Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Cytovance Biologics.
What is Cytovance Biologics's CDMO Signal Score?
Cytovance Biologics has a Signal Score of 79/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cytovance Biologics for a manufacturing program?
Use the free AI matchmaker to compare Cytovance Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Richter BioLogics
Hamburg, Germany
Signal Score: 82.9
Plasmid DNA, Recombinant Proteins, VHH/Nanobodies, Bacterial Vaccines, Biologics, Microbial Fermentation
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 82.9
Recombinant Protein, Plasmid DNA, mRNA, Microbial Fermentation
MicroBiopharm Japan
Tokyo, Japan
Microbial Fermentation, High-Potency APIs, Biologics
Nordmark Pharma
Uetersen, Schleswig-Holstein, Germany
Biologics, Microbial Fermentation, Clinical Trial Manufacturing, Oral Solid Dose
Compare Cytovance Biologics with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.